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Background: The ability to measure the concentrations of small damaging and signalling molecules such as
reactive oxygen species (ROS) in vivo is essential to understanding their biological roles. While a range of
methods can be applied to in vitro systems, measuring the levels and relative changes in reactive species in
vivo is challenging.
Scope of review: One approach towards achieving this goal is the use of exomarkers. In this, exogenous probe
compounds are administered to the intact organism and are then transformed by the reactive molecules in vivo
to produce a diagnostic exomarker. The exomarker and the precursor probe can be analysed ex vivo to infer the
identity and amounts of the reactive species present in vivo. This is akin to the measurement of biomarkers pro-
duced by the interaction of reactive species with endogenous biomolecules.
Major conclusions and general signiﬁcance: Our laboratories have developed mitochondria-targeted probes that
generate exomarkers that can be analysed ex vivo bymass spectrometry to assess levels of reactive species within
mitochondria in vivo. We have used one of these compounds, MitoB, to infer the levels of mitochondrial hydrogen
peroxidewithin ﬂies andmice. Herewe describe the development ofMitoB and expand on this example to discuss
howbetter probes and exomarkers can be developed. This article is part of a Special Issue entitled Currentmethods
to study reactive oxygen species - pros and cons and biophysics of membrane proteins. Guest Editor: Christine
Winterbourn.© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Relatively short-lived, reactive molecules occur in many different
contexts in biology [1,2]. Typical examples are the reactive oxygen
species (ROS) superoxide and hydrogen peroxide [3,4], but there
are many others including the reactive nitrogen species nitric oxideGFP, green ﬂuorescent protein;
l)benzyltriphenylphosphonium
ium bromide; ROS, reactive
methyltriphenylphosphonium;
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urphy).
blished by Elsevier B.V. All rights re(NO) and peroxynitrite [5], degradation products arising from oxidative
damage such as 4-hydroxynonenal (4-HNE) [6], and side products of
metabolic processes, such as methylglyoxal from glycolysis [7]. These
reactive species are of considerable interest because they can directly
damage other biological molecules and disrupt cell function, and also
they can act as signals tomodulate biological processes [1,2,8,9]. Conse-
quently many biologically important questions can only be addressed
fully by measuring the steady state levels and changes in these reactive
species in vivo [10,11].
Measurement of the concentrations of reactive molecules such as
superoxide, hydrogen peroxide andNO in biological environments is in-
herently challenging due to their short lifetimes, diverse chemistries
and the limited selectivity of detection systems [1,10,12]. It is possible
to apply more selective approaches in vitro such as using spin trapping
followed by electron paramagnetic resonance (EPR) spectroscopy to
ensure that only radical species are detected, or by using catalase- or
superoxide dismutase (SOD)-sensitive changes in the absorbance or
ﬂuorescence of detector molecules to provide robust and usefulserved.
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Fig. 1. The exomarker approach to assess levels of a reactive species in vivo. The probe is
administered to the organismwhere it is converted to a diagnostic exomarker product by
reaction with reactive species. The exomarker product is then extracted from the organ-
ism and analysed to infer the type and levels of reactive species that occur in vivo.
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questions it is often necessary to assess the level of the reactive species
in context, and with these more complicated systems the detection
methods are less selective and sensitive. In cell systems, general changes
in the ROS can be detected by determining the oxidation of probes such
as dichloroﬂuorescin to its ﬂuorescent product dichloroﬂuorescein,
although there are signiﬁcant limitations to the use and interpretation
of this probe [15]. The production of speciﬁc ROS such as superoxide
can be inferred, with certain caveats, by determining the changes in ﬂuo-
rescence of probes such as hydroethidine [14] or MitoSOX [16], or for
hydrogen peroxide by using boronic acid-conjugated ﬂuorophores
[17–19]. Another important approach is to utilise engineeredproteins de-
rived from green ﬂuorescent protein (GFP) such as redox sensitive GFP
(roGFP) or HyPer [20,21]. The ﬂuorescent intensity of these probes
responds to changes in endogenous redox couples or levels of hydrogen
peroxide and often has the signiﬁcant advantage that their ﬂuorescence
is ratiometric, thereby facilitating calibration, and that they can be direct-
ed to particular cell types and compartments [20–22]. These approaches
work well and produce robust and useful information, provided
artefactual effects are recognized and steps are taken to correct them
[15,20,23]. However, extension of these approaches from cells in culture
to intact living organisms is challenging. In some circumstances optical
techniques can be used, for example in the optically accessible surface
cell layers by the use of two photon microscopy [24], by the use of
chemoselective bioluminescent probes [25], or in transparent organisms
such as zebra ﬁsh embryos [26]. In general though, it is very difﬁcult to
measure directly the levels of small, reactive molecules within living
organisms.
Changes in reactive species in vivo are often inferred by measuring
the accumulation of oxidative damagemarkers derived from the interac-
tion of reactive species with protein, DNA or lipid [27–32]. While mea-
surements of oxidative damage markers are very informative, a major
limitation is that the actual amount of accumulation of a damagemarker
is determined not only by its rate of formation but also by the effective-
ness of repair processes and defencemechanisms, all of which vary inde-
pendently of each other [30,33]. Another possibility is to measure the
expression levels of genes that respond to alterations in a reactive spe-
cies, either as a damage response or as a redox signal [34,35]. However,
again there are multiple levels of regulation and feedback making the
link between the expression level of the particular gene and the amount
of a speciﬁc reactive species tenuous. The current situation is that while
changes in the levels of short-lived reactive molecules are often pro-
posed to mediate damage and redox signals in a range of biological situ-
ations in vivo, we do not have the techniques available to test these
hypotheses properly [10]. There is a critical unmet need for better mea-
surements of the levels of reactive species in vivo.
One approach that can be used to assess the levels and identities of
reactive species in vivo is by using exogenous marker molecules for
which we have coined the term “exomarkers”. This approach has
many parallels with the use of biomarkers whereby changes in the
levels of products, such as F2-isoprostanes, from the interaction of re-
active species with endogenous molecules are used to infer changes
in reactive species in vivo [32]. However, the use of exomarkers differs
in that an exogenous, artiﬁcial probe compound is administered to
the organism (Fig. 1). Within the organism the probe is modiﬁed by
reactive species to generate an exomarker product which is diagnostic
of the reactive species, and which then can be assessed and used to
infer levels of reactive species present in vivo (Fig. 1). Despite previously
lacking a unifying name, the concept of administering exogenous probe
molecules to a living organism in order to infer changes in reactive
species in vivo by the measurement of exomarkers is not new. It
has been used by a number of other groups in the past. For example,
the selective reactivity of spin traps with free radicals and the subse-
quent analysis of the products by EPR spectroscopy [36–38], or by a
combination of liquid chromatography and mass spectrometry [39,40]
has been extensively exploited within experimental animals. Similarly,a range of chemical traps such as salicylate, DMSO, phenylalanine,
4-hydroxybenzoic acid and terephthalic acid have been used to infer
the levels of hydroxyl radical production in vivo [12,41–47].
The ideal probe to generate an exomarker would have the following
properties: non-toxic; does not alter endogenous metabolism; easily ad-
ministered to the living organism; transports to a particular organ/tis-
sue/cell type and localises within a single cell compartment; reacts
selectively and efﬁciently with the target reactive species, with no
side reactions, to produce a stable product; the reaction to generate
the exomarker does not signiﬁcantly alter the levels of the reactive spe-
cies to be assessed; both the diagnostic exomarker and the probe are
easily assessed at very low levels, ideally in urine or plasma. It is also im-
portant that the probe is synthetically accessible and chemically stable,
and so an ideal probe is the simplest structure that fulﬁls all the
requirements.While these are demanding criteria,many exomarker ap-
proaches will still be useful if they meet only some of them.
Here we describe our experience to date with one class of exomarker
designed to report on mitochondrial ROS in vivo [11,48], discuss the
strengths and weaknesses of this approach and consider how it may be
extended and developed.
2. Assessing mitochondrial hydrogen peroxide in vivo with MitoB
In our laboratories one focus is to develop an understanding of the
role of mitochondrial ROS such as hydrogen peroxide in biological dam-
age and redox signalling [49–51]. The levels of mitochondrial hydrogen
peroxide in vivo were not known, therefore to address this unmet need
we developed an exomarker approach using a mitochondria-targeted
mass spectrometric probe called MitoB [11,48]. MitoB (Fig. 2A) is com-
prised of the lipophilic cationic triphenylphosphonium (TPP) moiety
linked to an arylboronic acid [11]. The TPP moiety has been used exten-
sively to drive the uptake of a range of bioactive molecules into mito-
chondria in vivo, including antioxidants, probes and nitric oxide donors
following oral, intravenous or intraperitoneal administration routes
[52–55]. The lipophilic nature of the TPPmoiety enables these molecules
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Fig. 2. Using MitoB to assess mitochondrial hydrogen peroxide formation in vivo. A: Reaction of MitoB with hydrogen peroxide or peroxynitrite converts the arylboronic component of
MitoB to a phenol, MitoP. B: Administration ofMitoB to an animalmodel such asDrosophila leads to the rapid accumulation ofMitoBwithin cells and from there intomitochondria, driven
by the plasma (Δψp) and mitochondrial (Δψm) membrane potentials. Consequently, MitoB is predominantly present within mitochondria in vivo. There MitoB will react with the local
concentration of hydrogen peroxide to form MitoP causing the ratio of MitoP/MitoB to increase. Experimentally, MitoB is injected into the animal and after 3–6 h incubation in vivo
the MitoP/MitoB ratio is determined by extracting MitoP and MitoB from the tissue and measuring them by liquid chromatography and tandem mass spectrometry. C: Mechanism of
the reaction of hydrogen peroxide with MitoB.
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cell driven by the plasmamembrane potential, and then further accumu-
late within mitochondria driven by the large mitochondrial membrane
potential (Fig. 2B) [53,56]. These lipophilic cations rapidly pass back
and forth across biological membranes, thereby equilibrating with the
local membrane potentials. The Nernst equation can adequately describe
this uptake and the accumulation within cells and mitochondria isextensive (increasing ~10-fold for every 60 mV of membrane potential)
with up to a thousand fold accumulation within mitochondria [56].
Consequently, attaching a small, non-polar moiety to a TPP molecule is
an effective way of rapidly targeting the molecule to the mitochondrial
compartment in vivo following many modes of administration [53,57].
In MitoB an arylboronic acid moiety is attached to the TPP function
[11], which reacts directly with the conjugate base of hydrogen
Time
Am
ou
nt Probe
Exomarker
Fig. 3. Time course of generation of exomarkers. Here it can be seen that a bolus admin-
istration of a probe leads to an initial high concentration in the organism that is then
lost over time by excretion. In contrast the exomarker is initially absent but its content
increases over time due to the reaction of the probe with the target reactive species.
Consequently the ratio of the exomarker to that of the initial probe increases over time.
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exploited by Chang who showed that the hydroxyl group in a
ﬂuorophore could be substituted with a boronate to generate a family
of hydrogen peroxide-selective ﬂuorescent probes [17–19,59]. These
probes showed appreciable selectivity for hydrogen peroxide over
other ROS and were a considerable improvement over other available
ﬂuorescent ROS probes because the reaction was non-enzymatic and
more chemically selective [17–19] (Fig. 2C). The Kalyanaraman labora-
tory has subsequently shown that arylboronates also react very rapidly
with peroxynitrite and hypohalous acids to generate the corresponding
phenol [60,61]. This work indicated that the arylboronic acid moiety
was a useful hydrogen peroxide-selective probe in a biological environ-
ment, provided that peroxynitrite and hypohalous acid production
could be managed or estimated independently, and therefore it was in-
corporated into the design process for MitoB [11]. Themode of action of
MitoB is shown in Fig. 2B: MitoB should accumulate rapidly within
mitochondria in vivo and there be converted slowly and irreversibly to
the phenol, MitoP, in direct proportion to the local hydrogen peroxide
concentration [11]. Therefore measurements of the accumulation of
the exomarker MitoP relative to the probe MitoB should be an indica-
tion of the average, local hydrogen peroxide concentrationwithinmito-
chondria over the duration of the experiment.
Experiments are carried out by injectingMitoB into a living organism,
for example into the thorax of Drosophila or intravenously into a mouse
[11,48,62]. This results in rapid delivery of MitoB to the mitochondria
within the tissues and the animal is then allowed to resume normal be-
haviour for 3 to 6 h. Over this period MitoB will be gradually lost from
theorganismby excretion, but in addition a proportionwill be converted
by reaction with hydrogen peroxide to MitoP. As theMitoB is essentially
present only in mitochondria, the conversion is dependent on the con-
centrations of MitoB and hydrogen peroxide within the mitochondria.
The uptake ofMitoB and the retention ofMitoP once formed are both de-
pendent on membrane potential and both will be lost from the body at
very similar rates [11]. Thus over time the ratio ofMitoP/MitoB in a tissue
will increase due to the MitoB to MitoP conversion, essentially integrat-
ing the averagemitochondrial hydrogen peroxide concentration present
over the duration of the experiment. By expressing the results as the
ratio of MitoP/MitoB over time the assay corrects for changes in the
uptake of MitoB into mitochondria in the tissue under consideration.
The amount of MitoP relative to MitoB in tissue samples was
measured by liquid chromatography–tandem mass spectrometry
(LC–MS/MS), normalised to deuterated internal standards [11].
This approach was chosen because the TPP cation has the further
advantage of a ﬁxed positive charge that greatly enhances the sensitivity
of detection by mass spectrometry. Derivatization with a TPP moiety is
widely used to enhance the sensitivity of detection bymass spectrometry
[63,64]. To quantify the amounts of MitoB and MitoP in a tissue sample,
the compounds are ﬁrst extracted from the tissue, separated by reverse
phase HPLC (RP-HPLC), introduced into a mass spectrometer and then
the precursor ion is broken up and the fragment ions measured by
tandem mass spectrometry [65,66]. These measurements are carried
out relative to deuterated internal standards of MitoB and MitoP that
are added to the biological sample prior to extraction and analysis in
order to correct for both inefﬁciencies in extraction and in the LC–MS/
MS assay [11]. MitoB incorporates the desirable features of a probe into
a very simple structure, so that MitoB, MitoP and the deuterated stan-
dards are easily prepared [11].
The use of MitoB has been described in detail in previous publica-
tions [11,48,62]. It has been used to assess changes in the production
of mitochondrial hydrogen peroxide in Drosophila with age [11]. In
this work MitoB was injected into anesthetized ﬂies that were
allowed to recover and ﬂy freely. Then, after 4 to 6 h, they were
harvested and the MitoP/MitoB ratio determined. This approach
allowed the average mitochondrial level of hydrogen peroxide to be
assessed in free living ﬂies for the ﬁrst time and showed that there
was an increase in average mitochondrial hydrogen peroxideconcentration with age, and that this was decreased by enhanced
physical activity [11]. MitoB was also applied to mammalian systems
and it was found that an intravenous injection of MitoB into a mouse
enabled sufﬁcient MitoB to be taken up into the heart to assess
changes in mitochondrial ROS production during ischemia–reperfusion
injury [62]. Therefore MitoB can be used as a probe to assess mitochon-
drial hydrogen peroxide production in vivo, through generation of
MitoP as an exomarker, and many other experimental models are
currently being interrogated using MitoB. In the next section, we use
MitoB as an example to discuss the strengths and weaknesses of
the exomarker approach and suggest how it can be extended and
improved.3. Critical considerations for the development of exomarkers
3.1. Mode of probe delivery in vivo
In the development of MitoB we found that delivery as a single
bolus by injection was preferable [11,48,62]. This enabled the probe
to be delivered to the required location essentially at the time of ad-
ministration and thereby enabled the accumulation of the exomarker
product to be interpreted more easily (Fig. 3). If the mode of delivery
was different, for example orally, the uptake into the tissue would be
spread over a longer time, making the kinetics of accumulation of the
exomarker derivativemore difﬁcult to assess. Formouse experiments, a
single injection of MitoB led to rapid delivery to mitochondria within
organs such as the heart [62]. This was due to the rapid clearance of
TPP compounds from the circulation into cells and mitochondria [57].
There is a concern that a probe, or its exomarker derivative, may redis-
tribute over time, howeverwith TPP compounds the rapid initial uptake
into organs due to their rapid passage through biological membranes
and their accumulation within cells and mitochondria renders the
steady-state levels in the circulation very low [57]. Furthermore, any
TPP compounds that redistribute back into the plasma are removed by
the kidneys and biliary excretion pathways [57,67,68]. Thus tissue re-
distribution is a minor concern for the TPP class of exomarker [57],
but for other probes and exomarkers that are not actively accumulated
secondary redistribution throughout the organismmay affect the inter-
pretation of the endpoint measurements. It may also be possible to de-
liver a probe to the desired location over a short time by other
approaches, for example, it may be possible to achieve a step change
in probe concentration in nematodes by soaking in concentrated liquid
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fresh incubation medium. Other modes of administration, for example
by gavage or by continual steady state delivery in the drinking water
or by infusion may also be useful in certain circumstances.Probe
Excretion
Reactive
species
Side
reactions
Side
reactions
Excretion
P
Exomarker
P E
E
Fig. 4. Potential fates of a probe in vivo. Once administered in vivo the probe, P, can be
excreted intact, undergo side reactions or react with the target reactive species to form
the diagnostic exomarker E. Then E itself can be excreted, or further modiﬁed.3.2. Location of the probe in vivo
The transformation of a probe to an exomarker is most informative
and easily interpreted if it is located in a deﬁned organ, cell type and
intracellular location. The approximately thousand fold greater local
concentration of MitoB within mitochondria, compared to the extracel-
lular environment, also enhances selectivity [11]. This is because the
rate of the reaction of MitoB with hydrogen peroxide is second order,
so the high local concentration of MitoB will in itself greatly increase
the selective reporting of mitochondrial reactive species, even if the
hydrogen peroxide concentration is the same in the cytosol and mito-
chondrial compartments.
The use of TPP to target molecules such as MitoB to mitochondria
is well established in isolated mitochondria, in cells and in vivo
[53–56,69]. These ﬁndings are based on extensive studies showing
that the uptake of a range of TPP compounds into isolatedmitochondria
and intomitochondriawithin cells occurs in response to the plasma and
mitochondrial membrane potentials and is described adequately by the
Nernst equation [53,54,56,69]. We havemade a series of TPP compounds
conjugated to thiol-reactive moieties which form stable, covalent attach-
ments to protein thiols that can be detected using antibodies against the
TPP moiety on western blots or by immunohistochemistry [70]. These
compounds only label mitochondria in cells in culture [57,69,70], and
also within mice [57] and ﬂies [11]. Administration of radiolabelled TPP
compounds to animals has showndistribution into tissues that is affected
by mitochondrial membrane potential [57,71]. Furthermore, TPP
conjugated to ﬂuorescent moieties shows essentially complete spa-
tial localisation within mitochondria in cells [16,17,72]. All these
studies on a wide range of TPP compounds suggest that MitoB and
MitoP will obey the Nernst equation and justify our assumption of
their mitochondria-selective accumulation in vivo [11]. Consequently
the whole organism or tissue can be assessed with conﬁdence that
any formation of the exomarker in non-mitochondrial locations is neg-
ligible [11]. A further point is that as the uptake into mitochondria of
MitoP and MitoB driven by the mitochondrial and plasma membrane
potentials is very similar [11], the accumulation of MitoP can be
normalised to that of MitoB. This ability to assess the ratio of the
probe and its exomarker product is a signiﬁcant advantage in correcting
for random alterations in uptake and distribution of the probe. For
example, measuring the MitoP/MitoB ratio enables a change in MitoB
uptake due to the mitochondrial membrane potential to be corrected
for by a similar change in MitoP retention. However in situations
where normalisation of the exomarker to the probe is not possible
then factors that affect the uptake or retention of the probe may affect
the production of the biomarker and must be considered.
A signiﬁcant weakness in this strategy is that only the average
mitochondrial content of reactive species over a time period within
a tissue is assessed. Thismay becomeacute if changes in reactive species
in a small number of cellswithin a tissue or organismare important, or a
short-term release of reactive species is involved, as these types of
changes would not be seen by the use of probes such asMitoB. Alterna-
tive approaches, such as cell speciﬁc targeting of proteins in conjunction
with optical methods would have to be used in these situations [22].
Alternatively it may be possible to design a probe, which, upon interac-
tion with the reactive species, is transformed into an exomarker that
was retained within the cell or organelle enabling ex vivo separation
prior to analysis. In principle, complementary targeting strategies
could be used to assess other intracellular or tissue locations in vivo
and their development would facilitate the development and useful-
ness of the exomarker approach.3.3. Selective reactivity and excretion of the probe and exomarker
A critical requirement for the efﬁcacy of the exomarker approach
is the selective alteration of the probe by the reactive molecule to
be assessed (Fig. 4). There are a number of fates for a probe molecule:
excretion, side reactions with other components within the biological
matrix and reactionwith the reactive species to generate the diagnostic
exomarker product. The ideal is a probe with no side reactions that
produces a single diagnostic exomarker product; furthermore the
exomarker should be stable and not biotransformed to othermolecules.
These criteria seem to be met for MitoB in Drosophila where the MitoB
reacts only with hydrogen peroxide to form MitoP. However the reac-
tion of MitoB with peroxynitrite may affect the interpretation of MitoP
accumulation under some conditions. There is also evidence that
arylboronic acids can react with hypohalous acids such as hypochlorous
acid to form a phenol [61], which may also affect the interpretation of
the results. In addition, the rate of reaction ofMitoBwith hydrogen per-
oxide is pH-dependent [11], consequently it is important to ensure that
alterations in the rate of accumulation of MitoP reﬂect changes in hy-
drogen peroxide concentration and not pH. When probing the level of
a reactive species in vivo it is useful if the reaction between the probe
and the reactive species to generate the exomarker is relatively slow
as otherwise it would distort the levels of the reactive species in vivo
and thereby modify biological function. It is important to note that
this slow rate of reaction of a probe with a reactive species does not
limit its usefulness even when there are many far faster endogenous
degradation pathways for the reactive species. For example, the rate
of reaction of MitoB with hydrogen peroxide is ~9 M−1 s−1 [11],
which is negligible compared to that of peroxidases such as
peroxiredoxin 3 where the rate is ~2 × 107 M−1 s−1 [73]. The probe
is not in competition with the other potential sinks for the reactive
species; instead it is reacting by a second order process with the target
species and thus responds to its steady state concentration. This steady
state will in turn be set by both the rates of formation and degradation
of the reactive species and changes in these will alter the levels of the
exomarker. Furthermore, a slow reaction rate between the probe and
the reactive species ensures the generation of the exomarker which re-
mains proportional to the reactive species' concentration, as the ratio of
exomarker to probe remains low. The downside of the slow rate of reac-
tion of the probe with the reactive species, such as in the case of MitoB,
is that it may take a long time for accumulation of sufﬁcient exomarker
to reach the threshold for detection. Consequently, probes such as
MitoB integrate the average level of the reactive species over a few
hours. This facilitates assessing the levels of reactive species in free liv-
ing animals under normal conditions as the compound can be adminis-
tered under anaesthesia and the animal followed as required for a few
hours. However, for this to work it is essential that the lifetime of the
probe in vivo is sufﬁcient to enable integration of the signal for this
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detection methods, hence the use of LC–MS/MS in conjunction with
deuterated standards.
3.4. Sampling of the probe and exomarker
An important aspect of using the exomarker approach to assess re-
active species within a living organism is to sample the accumulation
of the diagnostic exomarker effectively. In the case of MitoB, this was
done destructively by the extraction of the exomarker and its products
from the whole organism or organ. While this approach has the advan-
tage that different organs can be assessed independently, it would be
useful to be able to assess the exomarker non-destructively, for example
by analysing plasma or urine preferably in a dynamic mode. For MitoB
the rapid clearance of TPP compounds from the plasma precludes
plasma analysis. However, MitoB and MitoP are excreted into the
urine following injection into mice [11,48]. While the relationships be-
tween the levels that accumulate in urine and concentrations of reactive
species in mitochondria in vivo are unclear, future work assessing this
link may facilitate the non-destructive analysis of mitochondrial ROS
levels in vivo. This would make assessment of changes inmitochondrial
ROS during the development of a pathology or treatment possible and
might also enable this approach to be translated to human studies.
3.5. Analytic approaches to identify and quantify exomarkers
While there are a range of possible approaches for the ex vivo analysis
of an exomarker, one constraint is that the probe compounds are admin-
istered for a few hours to animals and thus the amounts detected are
small, necessitating very sensitive analytical approaches. The use of
LC–MS/MS relative to internal stable isotope standards currently
seems the most useful. Other approaches to analyse ex vivo samples,
such as EPR spectroscopy, HPLC with electrochemical detection or gas
chromatography may also be used for particular molecules under
certain circumstances. The LC–MS/MS approach combines sensitive
quantiﬁcation and accurate identiﬁcation with the possibility of
relatively high throughput. One constraint is the requirement for the
synthesis of stable isotope internal standards for identiﬁcation and
quantiﬁcation.
Most approaches reported to date require knowledge of the identity
of the reactive species, but it is likely that there are many similar com-
pounds that are important in vivo but which are currently unsuspected
due to the difﬁculties of analysis. Tandemmass spectrometry using pre-
cursor ion scanning in conjunction with broadly reactive probe trapsP+P P+E1
Reactive
species
Probe
Fig. 5. Using a probe in conjunction with precursor ion scanning to identify unknown reactiv
TPP moiety connected to the chemical trap P. In vivo the interaction with unknown reactiv
tandem mass spectrometry with precursor ion scanning mode to identify the precursors o
by mass. From this, the nature of the unknown reactive species that interacted with P to gethat generate a range of distinct exomarkersmay be oneway to identify
previously unknown reactive species, although this is not a high
throughput approach. For example, consider a mitochondria-targeted
TPP probe conjugated to a chemical trap E, chosen so that it wasmodiﬁed
by a range of reactive species (Fig. 5). The probe would react in vivo to
forma series of different exomarker products that can be analysedby tan-
demmass spectrometry in precursor ion scanningmode to pick up a dis-
tinctive fragment ion derived from the TPP moiety [11,48]. The mass of
the parent ion of the exomarker containing the TPP moiety can thereby
be determined and the nature of the reactive species inferred (Fig. 5).
4. Conclusion
Here we have outlined work to date on the mitochondria-targeted
mass spectrometry exomarker approach. In this we have suggested
that MitoB satisﬁes some of the criteria for an ideal probe to generate
the exomarker MitoP. At the moment we and others are building on
this work to generate further mitochondria-targeted probes to extend
the exomarker approach to analyse other reactive molecules within
mitochondria in vivo. The goal is to learn more about how changes
in reactive species contribute to pathologies and normal biological
function. The ability to target probes to mitochondria through the
use of the TPP cation has facilitated this work. However, there are
many other cellular compartments to target and the development of
alternative approaches to direct probes to these locations is an important
area for future development. The ex vivo analysis of exomarkers by mass
spectrometry hasmany advantages, but one problem is that thismethod-
ology is inherently invasive and another is the time-consuming nature of
the sample processing. The development ofmethods to assess changes in
exomarkers less invasively and in real time would greatly enhance their
usefulness.
The need to assess reactive species in vivo is clearly an important
goal. The continued development of probes and exomarkers is one
approach that shows promise to contributing to this unmet need.
However, as with all assessments of reactive species it must be applied
cautiously and the accuracy and robustness of the approach continually
probed and reassessed by orthogonal methods.
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